Clinical Trials · NCT02859064
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- SCRI Development Innovations, LLC
- Enrollment
- 6
- Start date
- Jul 2017
- Locations
- 3 sites, United States
- Primary endpoint
- Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability